Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Which drugs efficacy is most affected by methotrexate?

See the DrugPatentWatch profile for methotrexate

Which cancer or autoimmune drugs become less effective when you take methotrexate?

Methotrexate (MTX) can change the effectiveness and toxicity of several medicines because it affects folate pathways and is often used alongside other drugs that also rely on folate metabolism.

What’s most affected: folate-dependent drugs and antifolates

The main drug class most clearly affected by methotrexate involves folate metabolism. MTX is an antifolate, so drugs that depend on folate pathways can have their activity altered (either by functional “overlap” at the same pathway or by folate depletion effects).

Common examples searched in this space include other antifolates (such as pemetrexed or other folate-targeted anticancer drugs), and folate-dependent antimetabolites. In practical terms, this can mean reduced tolerability and, in some regimens, changes in effectiveness or dose feasibility—often leading clinicians to adjust timing and dosing.

Does methotrexate mainly reduce efficacy or increase side effects?

In many real-world interactions, MTX more reliably increases the risk of adverse effects (and forces dose changes) than it directly “cancels” efficacy. Drug choice and schedule often depend on the specific MTX dose (low weekly dosing for inflammatory disease vs higher dosing in some oncology settings), kidney function, and whether the other drug is also an antimetabolite or antifolate.

What should patients ask their clinician about?

Patients typically need to ask:
- whether their other medicine is also an antifolate or antimetabolite
- whether any leucovorin (folinic acid) “rescue” is part of the plan
- whether their MTX schedule should be separated from the other drug
- how kidney function affects MTX and interaction risk

Important gap: which exact drugs are “most affected” depends on the regimen

The question asks for specific drugs whose efficacy is most affected, but that depends on the clinical context (autoimmune MTX vs high-dose MTX in oncology) and the exact drug combination being considered. If you tell me the condition (e.g., rheumatoid arthritis, psoriasis, Crohn’s) and the other medication(s) you’re asking about, I can narrow it to the most relevant interactions.

Source

I don’t have the specific drug-interaction list you’re expecting from the provided materials here. If you share the country/regimen or the other drug names, I can answer precisely.



Other Questions About Methotrexate :

Does methotrexate impact children s growth rates? What are the risks of methotrexate use in older adults? Should methotrexate dosage be reduced in elderly patients with severe renal impairment? Can i take vitamins with methotrexate? What supplements should you not take with methotrexate? Methotrexate fda orange book exclusivity date? What pain medication can be taken with methotrexate?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade C

Partial

Mostly Aligned

Patient Risk: Info

Summary

Some mechanistic statements align with the provided labeling excerpt (MOA via dihydrofolate reductase and effects on DNA synthesis/replication), but several interaction-effect claims (e.g., reduced tolerability, efficacy cancellation vs adverse-effect predominance, and dependence on regimens) are not supported by the provided label sections (only MOA excerpt and partial dosing modifications/warnings headings).


Category Scores

Dosage
20
Poor
Warnings
35
Poor
Warnings
35
Poor
AdverseReactions
40
Poor

Accurate Statements

Methotrexate (MTX) is an antifolate.
Label section provided under 12.1: Methotrexate inhibits dihydrofolic acid reductase, interfering with synthesis of purine nucleotides and thymidylate via folate-dependent one-carbon carriers.
Methotrexate (MTX) can change the effectiveness and toxicity of several medicines because it affects folate pathways.
Label 12.1 Mechanism: Inhibits dihydrofolic acid reductase, reduces folate required for one-carbon group carriers used in purine and thymidylate synthesis; interferes with DNA synthesis/repair/replication in sensitive tissues.

Unsupported Statements

Drugs that depend on folate pathways can have their activity altered by methotrexate through overlap at the same pathway or through folate depletion effects.
Provided label excerpt describes methotrexate MOA and downstream effects, but does not describe folate depletion-driven interactions or pathway overlap mechanisms with other drugs.
Methotrexate interactions with other antifolates (such as pemetrexed) are an example of folate-pathway drug interaction.
No drug-drug interaction examples or mention of pemetrexed are present in the provided label excerpts.
Methotrexate interactions can result in reduced tolerability.
The provided excerpts include dosage modifications for various toxicities in general (e.g., myelosuppression, hepatotoxicity, pulmonary toxicity), but do not state that drug interactions cause reduced tolerability.
Methotrexate interactions can, in some regimens, change effectiveness or dose feasibility.
The provided excerpts do not describe interaction-specific effects on efficacy or dose feasibility.
In many real-world interactions, methotrexate more reliably increases the risk of adverse effects (and forces dose changes) than it directly cancels efficacy.
No comparative/relative-frequency statements or “real-world” generalizations are supported by the provided label excerpts.
Drug choice and schedule for methotrexate interactions depend on the specific MTX dose, kidney function, and whether the other drug is also an antimetabolite or antifolate.
The provided excerpts include a limited list of dosing modifications for adverse reactions but do not specify interaction-based regimen selection criteria, nor do they describe a dependence on kidney function or other-drug class for interaction management.

Contradictions


Important Omissions

No evaluation of contraindications, boxed warnings, or specific interaction warnings (e.g., detailed interaction section content) was possible because no label text for contraindications/boxed warnings/drug interactions was provided beyond the empty 7 DRUG INTERACTIONS section header and limited dosing-modification lists.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Info
Unsupported interaction-effect claims (especially regimen-dependence, interaction-driven tolerability, and efficacy changes) could mislead, but no explicit patient-management instructions were provided in the claims beyond general statements; provided label excerpts do not corroborate these interaction assertions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Several drug-interaction and consequence claims are not supported by the provided label excerpts.

Suggested Improvement
Limit statements to the provided MOA (inhibition of dihydrofolate reductase, effects on DNA synthesis/replication) and remove or qualify interaction-specific claims unless the corresponding FDA label drug-interaction text is provided.

Drug Brand Mention Assessment

Branding Score
48
Visibility
38
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
mentioned only
Brand Perception
Best Known For

Methotrexate (MTX) can change the effectiveness and toxicity of several medicines


Core Claims
  • Methotrexate (MTX) can change the effectiveness and toxicity of several medicines.
  • MTX is an antifolate, so drugs that depend on folate pathways can have their activity altered.
Differentiators
  • Affects folate pathways
  • Increases risk of adverse effects more reliably than it directly cancels efficacy

Pricing Perception: Not Mentioned